Osmosis Investment Management UK Ltd Takes $500,000 Position in Quest Diagnostics Incorporated $DGX

Posted by Geri Gentry on Aug 26th, 2026

Osmosis Investment Management UK Ltd purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,358 shares of the medical research company’s stock, valued at approximately $500,000.

Several other hedge funds have also recently made changes to their positions in the stock. Sanctuary Advisors LLC bought a new position in Quest Diagnostics during the second quarter valued at approximately $5,686,000. Jericho Financial LLP bought a new stake in Quest Diagnostics in the 2nd quarter worth approximately $344,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Quest Diagnostics during the 2nd quarter valued at $660,000. Meiji Yasuda Asset Management Co Ltd. purchased a new stake in Quest Diagnostics during the 2nd quarter valued at $624,000. Finally, Te Ahumairangi Investment Management Ltd bought a new position in shares of Quest Diagnostics during the 2nd quarter valued at $6,490,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Stock Up 0.3%

DGX opened at $244.59 on Wednesday. The firm’s 50 day simple moving average is $221.07 and its two-hundred day simple moving average is $206.09. The company has a market capitalization of $27.00 billion, a PE ratio of 25.96, a PEG ratio of 2.25 and a beta of 0.56. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $246.00. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The firm had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, equities analysts forecast that Quest Diagnostics Incorporated will post 11.15 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s payout ratio is currently 36.52%.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president owned 13,510 shares in the company, valued at $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the transaction, the chief executive officer directly owned 132,423 shares in the company, valued at $25,708,601.22. This trade represents a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,747 shares of company stock worth $3,947,088 over the last quarter. 0.88% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on DGX. Weiss Ratings upgraded Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday, August 12th. Argus set a $260.00 price objective on Quest Diagnostics in a research report on Wednesday, July 29th. JPMorgan Chase & Co. increased their target price on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Robert W. Baird raised their target price on Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Finally, Mizuho boosted their price target on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $235.31.

Get Our Latest Stock Report on Quest Diagnostics

About Quest Diagnostics

(Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.